‘Disadvantaged’ Gilead flipped partner negotiations into M&A discussion ahead of $4.9B Forty Seven deal
How Forty Seven turned conversations with potential partners into a two-horse race for a buyout
As four companies negotiated for partnerships with Forty Seven around its lead asset, magrolimab, Gilead’s relative commercial weakness in cancer appeared to inspire the company to seek an M&A deal instead, leading to the eventual $4.9 billion offer that Forty Seven accepted early last week.
Forty Seven Inc. (NASDAQ:FTSV) CEO Mark McCamish told BioCentury on Wednesday that Gilead Sciences Inc. (NASDAQ:GILD) may have been “disadvantaged” compared with other parties working to complete a deal. Instead, Gilead